Increased blood pressure (BP) may stimulate vascular inflammation, which may itself induce pathological arterial changes. BP variability has been associated with target-organ damage and future cardiovascular complications. We hypothesized that BP variability, as derived from ambulatory BP monitoring, is related to inflammatory markers in newly diagnosed hypertension. Systolic (S) and diastolic (D) BP variabilities were assessed as the SD of 24-h pressure recordings in a cohort of 190 recently (<6 months) diagnosed, untreated hypertensive subjects. Target organ damage, assessed by measuring the carotid artery intimamedia thickness, left ventricular mass index, and microalbuminuria, was related to plasma high-sensitivity C-reactive protein (hsCRP) and soluble (s) E-selectin, an endothelium-specific molecule. The patients' age (mean±SD) was 53.0±8.5 years, and 59% were male. Multivariable analysis identified awake SBP variability (95% confidence interval [CI]: 0.002−0.042, p=0.034) as an independent correlate of hsCRP and awake SBP (95% CI: 0.003−0.014, p=0.003), awake SBP variability (95% CI: 0.003−0.035, p=0.018), and microalbuminuria (95% CI: 0.075−0.280, p=0.001) as independent correlates of sE-selectin. When patients were divided into low and high awake SBP variability groups, age (p=0.001), hsCRP (p=0.0001), and sE-selectin (p=0.005) were significantly different in the two groups. After adjusting for age, these differences remained significant (p=0.022 and p=0.001 for hsCRP and sE-selectin, respectively). In recently diagnosed hypertensive subjects, hsCRP and sE-selectin levels are related to awake SBP variability. High SBP variability is likely associated with vascular inflammation in newly diagnosed hypertension, independent of SBP.
Libby P, Ridker PM, Maseri A : Inflammation and atherosclerosis. Circulation 2002; 105: 11357–1143.
Savoia C, Schiffrin EL : Inflammation in hypertension. Curr Opin Nephrol Hypertens 2006; 15: 152–158.
Lund-Johanson P : Haemodynamics in early essential hypertension: still an area of controversy. J Hypertens 1983; 1: 209–213.
Schiffrin EL : Reactivity of small blood vessels in hypertension: relation with structural changes. State of the art lecture. Hypertension 1992; 19: II1–II9.
Schiffrin EL : Resistance arteries as endpoints in hypertension. Blood Press Suppl 1997; 2: 24–30.
Bakker EN, van der Meulen ET, van den Berg BM, et al: Inward remodeling follows chronic vasoconstriction in isolated resistance arteries. J Vasc Res 2002; 39: 12–20.
Blake GJ, Rifai N, Buring JE, et al: Blood pressure, C-reactive protein, and risk of future cardiovascular events. Circulation 2003; 108: 2993–2999.
Ballantyne CM, Entman ML : Soluble adhesion molecules and the search for biomarkers for atherosclerosis. Circulation 2002; 106: 766–767.
Pradhan AD, Rifai N, Ridker PM : Soluble intercellular adhesion molecule-1, soluble vascular adhesion molecule-1, and the development of symptomatic peripheral arterial disease in men. Circulation 2002; 106: 820–825.
Pepys MB, Hirschfield GM : C-reactive protein: a critical update. J Clin Invest 2003; 111: 1805–1812.
Sesso HD, Buring JE, Rifai N, et al: C-reactive protein and the risk of developing hypertension. JAMA 2003; 290: 2945–2951.
Lakoski SG, Cushman M, Palmas W, et al: The relationship between blood pressure and C-reactive protein in the Multi-Ethnic Study of Atherosclerosis (MESA). J Am Coll Cardiol 2005; 46: 1869–1874.
Intengan HD, Schiffrin EL : Vascular remodeling in hypertension: roles of apoptosis, inflammation, and fibrosis. Hypertension 2001; 38: 581–587.
Verma S, Wang CH, Li SH, et al: A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 2002; 106: 913–919.
Engstrom G, Janzon L, Berglund G, et al: Blood pressure increase and incidence of hypertension in relation to inflammation-sensitive plasma proteins. Arterioscler Thromb Vasc Biol 2002; 22: 2054–2058.
De Caterina R, Gimbrone MJ : Leukocyte-endothelial interactions and the pathogenesis of atherosclerosis, in Kristensen SD, Schmidt EB, De Caterina R, Endres S (eds): n-3 Fatty Acids: Prevention and Treatment in Vascular Disease. London, Springer, 1995, pp 10–24.
Li JJ, Chen JL : Inflammation may be a bridge connecting hypertension and atherosclerosis. Med Hypotheses 2005; 64: 925–929.
Blann AD, Tse W, Maxwell SJ, et al: Increased levels of the soluble adhesion molecule E-selectin in essential hypertension. J Hypertens 1994; 12: 925–928.
De Caterina R, Ghiadoni L, Taddei S, et al: Soluble Eselectin in essential hypertension: a correlate of vascular structural changes. Am J Hypertens 2001; 14: 259–266.
Frattola A, Parati G, Cuspidi C, et al: Prognostic value of 24hour blood pressure variability. J Hypertens 1993; 11: 1133–1137.
Sander D, Kukla C, Klingelhofer J, et al: Relationship between circadian blood pressure patterns and progression of early carotid atherosclerosis: a 3-year follow-up study. Circulation 2000; 102: 1536–1541.
Sega R, Corrao G, Bombelli M, et al: Blood pressure variability and organ damage in a general population: results from the PAMELA study (Pressioni Arteriose Monitorate E Loro Associazioni). Hypertension 2002; 39: 710–714.
Wang JG, Staessen JA, Franklin SS, et al: Systolic and diastolic blood pressure lowering as determinants of cardiovascular outcome. Hypertension 2005; 45: 907–913.
Tatasciore A, Renda G, Zimarino M, et al: Awake systolic blood pressure variability correlates with target-organ damage in hypertensive subjects. Hypertension 2007; 50: 325–332.
Chobanian AV, Bakris GL, Black HR, et al: Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206–1252.
Mancia G, De Backer G, Dominiczak A, et al: 2007 Guidelines for the Management of Arterial Hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105–1187.
Pickering TG, Hall JE, Appel LJ, et al: Recommendations for blood pressure measurement in humans and experimental animals: Part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Hypertension 2005; 45: 142–161.
Parati G : Blood pressure variability: its measurement and significance in hypertension. J Hypertens Suppl 2005; 23: S19 – S25.
Bilo G, Giglio A, Styczkiewicz K, et al: How to improve the assessment of 24-h blood pressure variability. Blood Press Monit 2005; 10: 321–323.
Rifai N, Tracy RP, Ridker PM : Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem 1999; 45: 2136–2141.
Ferri C, Desideri G, Baldoncini R, et al: Early activation of vascular endothelium in nonobese, nondiabetic essential hypertensive patients with multiple metabolic abnormalities. Diabetes 1998; 47: 660–667.
Parissis JT, Korovesis S, Giazitzoglou E, et al: Plasma profiles of peripheral monocyte-related inflammatory markers in patients with arterial hypertension. Correlations with plasma endothelin-1. Int J Cardiol 2002; 83: 13–21.
Festa A, D'Agostino R Jr, Howard G, et al: Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000; 102: 42–47.
Ridker PM, Hennekens CH, Buring JE, et al: C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836–843.
Sung KC, Suh JY, Kim BS, et al: High sensitivity C-reactive protein as an independent risk factor for essential hypertension. Am J Hypertens 2003; 16: 429–433.
Schillaci G, Pirro M, Gemelli F, et al: Increased C-reactive protein concentrations in never-treated hypertension: the role of systolic and pulse pressures. J Hypertens 2003; 21: 1841–1846.
Bautista LE, Atwood JE, O'Malley PG, et al: Association between C-reactive protein and hypertension in healthy middle-aged men and women. Coron Artery Dis 2004; 15: 331–336.
Stumpf C, John S, Jukic J, et al: Enhanced levels of platelet P-selectin and circulating cytokines in young patients with mild arterial hypertension. J Hypertens 2005; 23: 995 – 1000.
Chae CU, Lee RT, Rifai N, et al: Blood pressure and inflammation in apparently healthy men. Hypertension 2001; 38: 399–403.
Abramson JL, Lewis C, Murrah NV, et al: Relation of Creactive protein and tumor necrosis factor-alpha to ambulatory blood pressure variability in healthy adults. Am J Cardiol 2006; 98: 649–652.
Kim KI, Lee JH, Chang HJ, et al: Association between blood pressure variability and inflammatory marker in hypertensive patients. Circ J 2008; 72: 293–298.
Ridker PM : C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus. J Am Coll Cardiol 2007; 49: 2129–2138.
Lasky LA : Selectin-carbohydrate interactions and the initiation of the inflammatory response. Annu Rev Biochem 1995; 64: 113–139.
Buemi M, Allegra A, Aloisi C, et al: Cold pressor test raises serum concentrations of ICAM-1, VCAM-1, and E-selectin in normotensive and hypertensive patients. Hypertension 1997; 30: 845–847.
Palomo I, Marin P, Alarcon M, et al: Patients with essential hypertension present higher levels of sE-selectin and sVCAM-1 than normotensive volunteers. Clin Exp Hypertens 2003; 25: 517–523.
Boulbou MS, Koukoulis GN, Makri ED, et al: Circulating adhesion molecules levels in type 2 diabetes mellitus and hypertension. Int J Cardiol 2005; 98: 39–44.
Glowinska B, Urban M, Peczynska J, et al: Soluble adhesion molecules (sICAM-1, sVCAM-1) and selectins (sE selectin, sP selectin, sL selectin) levels in children and adolescents with obesity, hypertension, and diabetes. Metabolism 2005; 54: 1020–1026.
Pedrinelli R, Dell'Omo G, Di Bello V, et al: Low-grade inflammation and microalbuminuria in hypertension. Arterioscler Thromb Vasc Biol 2004; 24: 2414–2419.
Clement DL, De Buyzere ML, De Bacquer DA, et al: Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. N Engl J Med 2003; 348: 2407–2415.
About this article
Cite this article
Tatasciore, A., Zimarino, M., Renda, G. et al. Awake Blood Pressure Variability, Inflammatory Markers and Target Organ Damage in Newly Diagnosed Hypertension. Hypertens Res 31, 2137–2146 (2008). https://doi.org/10.1291/hypres.31.2137
- blood pressure variability
- target-organ damage
- C-reactive protein
American Journal of Hypertension (2020)
From short‐term blood pressure variability to atherosclerosis: Relative roles of vascular stiffness and endothelial dysfunction
The Journal of Clinical Hypertension (2020)
Visit-to-visit blood pressure variability in patients with type 2 diabetes with and without previous history of cardiovascular disease
Journal of Hypertension (2020)
The Association Between Selected Molecular Biomarkers and Ambulatory Blood Pressure Patterns in African Chronic Kidney Disease and Hypertensive Patients Compared With Normotensive Controls: Protocol for a Longitudinal Study
JMIR Research Protocols (2020)
Journal of Hypertension (2020)